EUVIMEDEUVIMED entdecken
Crossref

Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database

Yaxin Zhang, Jing Ye, Jinming Chen, Jianuo Chen, Yinxia Wu, Jie Yang, Xiaoyan Wu

Cardiovascular Toxicology · 2026

DOI: 10.1007/s12012-025-10088-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Toxicology, 2026. Verfasst von Yaxin Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, 323000, China. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Antihypertensive Agents, Arterial Pressure, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Zhejiang Traditional Chinese Medicine Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotatercept (brand name "Winrevair") is a novel activin receptor type IIA (ActRIIA) fusion protein. Sotatercept has received FDA approval for WHO Gloup 1 pulmonary arterial hypertension (PAH) in 2023. While clinical trials demonstrated efficacy, comprehensive real-world safety data are lacking. Food and Drug Adverse Event Reporting System (FAERS) reports from Q1 2024 to Q1 2025 involving Sotatercept were analyzed. After data cleaning and standardization using MedDRA v27.1, reports where Sotatercept was the primary suspect drug (PS) were identified. Disproportionality analysis employed four algorithms: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Onset time analysis was performed. Among 2748 eligible reports, 72.8% involved females, predominantly aged 16-64.9 years. The most frequent System Organ Classes (SOCs) were general disorders and administration site condition (19.29%), gastrointestinal disorders (13.8%), and investigations (13.4%). The first 30 adverse events (AEs) mainly included headache (n = 124), epistaxis (n = 88), hemoglobin increased (n = 81), dizziness (n = 61), and platelet count decreased (n = 42). AEs can still occur after one year of use. This large-scale FAERS analysis identifies signals consistent with known AEs observed during Sotatercept use and identifies novel potential serious safety signals: pulmonary arteriovenous fistula and pericardial effusion. Enhanced monitoring is required, especially of hematologic parameters, bleeding risk, and cardiopulmonary complications during initial treatment. Further investigation into these signals' mechanisms is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionAntihypertensive AgentsArterial PressureRecombinant Fusion ProteinsPulmonary ArteryHumansFemaleDatabases, FactualTreatment OutcomeAdverse Drug Reaction Reporting SystemsPharmacovigilanceMaleAdultAdolescentYoung AdultRisk FactorsRisk AssessmentTime FactorsActivin Receptors, Type II

Stichwörter der Autor:innen

Food and drug adverse event reporting systemPulmonary arterial hypertensionSotatercept

Substanzen

Antihypertensive AgentsRecombinant Fusion ProteinssotaterceptActivin Receptors, Type II

Autor:innen und Institutionen

  • Department of Infectious Diseases, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, 323000, China.
  • Department of Infectious Diseases, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, 323000, China. 1dao@sina.com.
  • Department of Cardiology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, 323000, China. smallbirdwu@126.com.

Förderung

  • Zhejiang Traditional Chinese Medicine Science and Technology Project

Zitieren

APA

Zhang, Y., Ye, J., Chen, J., Chen, J., Wu, Y., Yang, J., & Wu, X. (2026). Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-025-10088-2

Vancouver

Zhang Y, Ye J, Chen J, Chen J, Wu Y, Yang J, et al. Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database. Cardiovascular Toxicology. 2026. doi:10.1007/s12012-025-10088-2

BibTeX
@article{Zhang2026,
  author = {Zhang, Yaxin and Ye, Jing and Chen, Jinming and Chen, Jianuo and Wu, Yinxia and Yang, Jie and Wu, Xiaoyan},
  title = {Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database},
  journal = {Cardiovascular Toxicology},
  year = {2026},
  doi = {10.1007/s12012-025-10088-2}
}
Kostenlos starten →